Love CEMP, out of TTPH yesterday on the open. Annoyed by ACAD on upgrade declline, missed the top tick but 4 cents, so no position adjustment today except for one IRA account. Like owning NBIX, PTLA, HALO, XON.
Meanwhile, pssst, somebody knows something. Only explanation for strength.
H.C. Wainwright initiated coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Buy rating and a price target of $50.00.
Analyst Andrew S. Fein said, "In the often-tenuous world of psycho-therapeutics, we believe that Acadia represents a good long opportunity in the near-to-medium term, and an excellent long opportunity in the distant term. The company s main value driver, Nuplazid, is aimed at the untapped sub-indication, psychosis in Parkinson s disease (Phase 3 win in 2013, Breakthrough Therapy designation in 2014, NDA submission pending in 1Q15, potential launch in 1Q16 assuming approval), while also setting its sight on the more lucrative, albeit challenging, Alzheimer s disease psychosis (Phase 2 readout in 1H16). Importantly, aside from the long opportunity, we highlight that catalysts in the next 12 months may present opportunities and trading patterns appealing to short-term investors."
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $37.62 yesterday.
Google Harry Boxer Charts of the Day
An appearnce that only the SEC and FDA could love. He did nothing to warrant their attention. Just the facts ma'am..
when I told him my gastroenterologist guy was late for a 1:00 appointment. When I asked about the safety, he said sure it's safe, I've done 13 of them this morning. (Ka-ching)
Different than endoscopy, but the max turnover max dollars mentality sure doesn't help.
like MRK, PFE, BMY etc. A cash deal is would hurt too much tax-wise
Listen to and get the slide deck for the Oppenheimer presentation.
worldsworsttrader posted the link at stocktwits
Leerink presentation good too.
Or do we still use the old numbers as if only float increased not outstanding? I'll have to read the 8ks
They'll drive a harder bargain, we just have to trust their judgment and be as patient as they are.
Calculation if outstanding increased: 46.75% ownership (Yahoo number) X old shares outstanding 35.8 / new shares outstanding 41.2
What is the deadline for the holder's frim, seems to be teh rule.
Frome the CBOE site
The owner of an equity option can exercise the contract at any time prior to the exercise deadline set by the investor's brokerage firm. Generally this deadline occurs on the option's last day of trading. The expiration date for equity options is the Saturday immediately following the third Friday of the expiration month until February 15, 2015. On and after February 15, 2015, the expiration date will be the third Friday of the expiration month. If this third Friday happens to be an exchange holiday, then the last day is the third Thursday of the month. Check with your brokerage firm about its procedures and deadlines for instruction to exercise any equity options. After the option's expiration date, the equity option will cease to exist.
Yahoo still has 35.8 like the October number.
So $ 29.60 is about $1.2 billion market cap.
$6 billion would be about $157 per share. Not a lot of debt here. $6 billion would be a start to what the value is here, higher when fully de-risked.
Just my opinion.
I have 5 times as many shares of CEMP as TTPH, so I have voted my beliefs.
Plus Prahava Fernandes is one of the coolest CEOs ever.
and really lights the imagination of the Street,
Similar market cap, but I believe the potential revenues for soli are much higher.
Prabha Fernandes and the mass of insiders and others like me would require a much higher price.